About US
Contact us
-
Kinex Pharma gets FDA orphan drug status for glioma drugUS-based Kinex Pharmaceuticals has received orphan drug designation from the US Food and Drug Administration (FDA) for its dual src/pre-tubulin inhibitor 'KX02' to treat gliomas, which are the most co2013/12/6
-
OncoMed and Celgene to develop new multiple anti-cancer stem cell therapeuticsOncoMed Pharmaceuticals and Celgene have agreed to jointly develop and commercialise up to six therapies targeting cancer stem cells (CSCs) product candidates from OncoMed's biologics pipeline, includ2013/12/5
-
SP Scientific Announces its Winter 2013 Lyophilisa​tion Webinar ProgrammeDue to run on 22 January 2014, is a new webinar entitled 'Secondary Drying Optimization for Proteinaceous Drug Formula' chaired by Lisa M Hardwick — a highly experienced scientist from Baxter Biopharm2013/12/5
-
Sources: Bayer and others are kicking the tires on Novartis' animal health businessOnly a few weeks ago, word emerged that Novartis ($NVS) was weighing a sale or spinoff of itsanimal healthunit as part of a larger strategy by incoming chairmanJoerg Reinhardtto refocus the company. N2013/12/4
-
Apotex ordered to pay AstraZeneca half its generic Prilosec profitsAn award of $76 million may not sound like much in the big-dollar world of pharma, but for a branded drug company, it always feels good to win one against a generic drugmaker that has jumped the gun w2013/12/4
-
Rise of Generics and Patent Expirations Sees CPhI and P-MEC India 2013 ExpandCPhI announces that CPhI and P-MEC India, ran by leading events organiser UBM, is returning to the Bombay Convention and Exhibition Centre, Mumbai (India) 3–5 December 2013. The event will return with2013/12/3
-
Vifor Pharma's hyperphosphatemia drug Velphoro gets FDA approvalThe US Food and Drug Administration (FDA) has approved Vifor Pharma's hyperphosphatemia drug Velphoro for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialys2013/12/3
-
Novartis Foundation Launches New Leprosy Strategy at Symposium on Disease EliminationToday's symposium of the Novartis Foundation for Sustainable Development (NFSD) convenes experts to discuss "What does it take to eliminate a disease?" Drawing lessons from previous successful disease2013/12/2
-
Rx-360 Applauds Passage of Drug Quality and Security ActRx-360 applauds the passage of the bipartisan Drug Quality and Security Act, H.R. 3204. The Act was approved by the House of Representatives in September and by the Senate on 18 November. President Ob2013/12/2
-
FDA Warning Letter Statistics 2013 Regarding Process Validation/Qualification/CalibrationIn 2013, process validation was at the top of the critised deviations. Missing or insufficient process validation was quoted 15 times. The most frequent critics were made to dosage forms (five times)2013/11/29